8-2015

Versatility of using major histocompatibility complex class II dextramers for derivation and characterization of antigen-specific, autoreactive T cell hybridomas

Bharathi Krishnan  
University of Nebraska-Lincoln, bkrishnan2@unl.edu

Chandirasegaran Massilamany  
University of Nebraska-Lincoln, cmassilamany@unl.edu

Rakesh H. Basavalingappa  
University of Nebraska-Lincoln, rakesh@unl.edu

Rajkumar A. Rajasekaran  
University of Nebraska-Lincoln, rajkumar.ar@unl.edu

Charles Kuszynski  
University of Nebraska-Lincoln, ckuszynski2@unl.edu

See next page for additional authors

Follow this and additional works at: http://digitalcommons.unl.edu/vbsjayreddy

Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Krishnan, Bharathi; Massilamany, Chandirasegaran; Basavalingappa, Rakesh H.; Rajasekaran, Rajkumar A.; Kuszynski, Charles; Switzer, Barbara; Peterson, Daniel A.; and Reddy, Jay, "Versatility of using major histocompatibility complex class II dextramers for derivation and characterization of antigen-specific, autoreactive T cell hybridomas" (2015). Jay Reddy Publications. 28.  
http://digitalcommons.unl.edu/vbsjayreddy/28

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Jay Reddy Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Versatility of using major histocompatibility complex class II dextramers for derivation and characterization of antigen-specific, autoreactive T cell hybridomas

Bharathith Krishnan, Chandirasegaran Massilamany, Rakesh H. Basavalingappa, Rajkumar A. Rajasekaran, Charles Kuszynski, Barbara Switzer, Daniel A. Peterson, and Jay Reddy

1 School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE 68583
2 Nebraska Center for Virology, University of Nebraska–Lincoln, Lincoln, NE 68583
3 College of Medicine, Dean’s Research Laboratory, University of Nebraska Medical Center, Omaha, NE 68918
4 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21205

Corresponding author — J. Reddy, Room 202, Bldg VBS, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE 68583, USA; email nreddy2@unl.edu

Abstract

Antigen-specific, T cell hybridomas are useful to study the cellular, molecular and functional events, but their generation is a lengthy process. Thus, there is a need to develop robust methods to generate the hybridoma clones rapidly in a short period of time. To this end, we have demonstrated a novel approach using major histocompatibility complex (MHC) class II dextramers to generate T cell hybridomas for an autoantigen, proteolipid protein (PLP) 139–151. Using MHC class II dextramers assembled with PLP 139–151 as screening and sorting tools, we successfully obtained mono antigen-specific clones within seven to eight weeks. In conjunction with other T cell markers, dextramers permitted phenotypic characterization of hybridoma clones for their antigen specificity in a single step by flow cytometry. Importantly, we achieved successful fusions using dextramer+ cells sorted by flow cytometry as a starting population, resulting in direct identification of multiple antigen-specific clones. Characterization of selected clones led us to identify chemokine receptor, CCR4+ to be expressed consistently, but their cytokine-producing ability was variable. Our work provides a proof-of-principle that the antigen-specific, CD4 T cell hybridoma clones can be generated directly using MHC class II dextramers. The availability of hybridoma clones that bind dextramers may serve as useful tools for various in vitro and in vivo applications.

Keywords: T cell, hybridoma, MHC, class II dextramers, Autoreactive T cells

Abbreviations: MHC, major histocompatibility complex; PLP, proteolipid protein; TCR, T cell receptor; LDC, limiting dilution cloning; TMEV, Theiler’s murine encephalomyelitis virus; CFA, complete Freund’s adjuvant; M.tb, Mycobacterium tuberculosis; RT, room temperature; LNCs, lymph node cells; IL, interleukin; FBS, fetal bovine serum; Con-A, concanavalin-A; PEG, polyethylene glycol; HAT, hypoxanthine/aminopterin/thymidine; HT, hypoxanthine/thymidine; 7-AAD, 7-aminoactinomycin-D; [H], tritiated; CCRs, chemokine receptors; PMA, phorbol 12-myristate-13 acetate; IFN, interferon; TNF, tumor necrosis factor.

1. Introduction

T cell hybridomas are useful tools for studying antigen-specific cellular, molecular, and functional events at a monoclonal level (Kubota and Iwabuchi, 2014; Rock, 1985; Rock and Benacerraf, 1983; Schrader and Clark-Lewis, 1982; White et al., 2000; Kruisbeek, 2001). Unlike primary T cell clones, which may eventually lose their antigen specificity over a period of time if left unstimulated, T cell hybridomas can maintain antigen specificity for extended periods of time because of their inherent ability to grow continuously in cultures (Rock, 1985; White et al., 2000; Kruisbeek, 2001).

T cell hybridomas are generated through fusion of antigen-sensitized effector T cells with mouse thymoma-derived BW5147 αβ T cell receptor (TCR)−/− cells, leading to the expression of only the TCRs specific to the fused T cells (Rock, 1985; White et al., 2000; Kruisbeek, 2001; Kubota, 2006). However, the screening procedure for antigen specificity is a laborious process (Rock, 1985). Generally, CD4 T cell hybridomas are screened based on cytokine secretion in response to antigen stimulations, and individual clones are then obtained mainly by limiting dilution cloning (LDC) (Rock, 1985; Kruisbeek, 2001; Peterson et al., 1999). Other methods include dispersion in soft agar, micromanipulation and flow cytometry (Rock, 1985). All these methods require expertise with the individual screening systems, making them both less practical and less desirable. For example, LDC is a labor-intensive, time-consuming procedure, because the cells need to be diluted to a low density (2 to 3 cells/ml), followed by screening of individual clones for their antigen specificity (Rock, 1985; Lefkovits and Waldmann, 1984). At least 25 such clones must be verified repeatedly to obtain a single antigen-specific clone, and the entire process to derive antigen-specific hybridoma clones can take up to three months or longer, or, the fusions may need to be repeated (Rock, 1985; Kruisbeek, 2001). Thus, there is a critical need to develop robust methods to derive T cell hybridoma clones quickly and efficiently in a shorter period of time.
We previously reported creation of the next generation of major histocompatibility complex (MHC) class II tetramers, designated "dextramers," which enabled us to detect and enumerate the precursor frequencies of autoreactive, antigen-specific CD4 T cells in a variety of systems (Massilamany et al., 2011a, 2014a, 2014b). Structurally, dextramers contain dextran molecules (polymers of glucose), each carrying up to seven streptavidin moieties to which multiple biotinylated MHC/peptide monomers can be assembled. Thus, dextramers can engage more TCRs than that could be achieved with tetramers (Massilamany et al., 2011a). We demonstrated that MHC class II dextramers exhibited greater sensitivity and specificity than could be achieved with MHC class II tetramers in several autoantigens, such as proteolipid protein (PLP) 139–151, myelin oligodendrocyte glycoprotein 35–55, and cardiac myosin heavy chain-α 334–352 (Massilamany et al., 2011a). Using PLP 139–151 dextramers as screening tools, we have devised a novel approach for rapidly deriving antigen-specific T cell hybridoma clones within 7 to 8 weeks. Importantly, dextramer-assisted sorting of antigen-specific clone donors allowed us to evaluate the expression of T cell markers, TCRs, and their Vβ-usage in a single step by flow cytometry, including cytokine secretion and chemokine receptor expression.

2. Materials and methods

2.1. Ethics statement

Five-to-six-week-old female SJL/J (H-2b) mice were procured from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained in accordance with the animal protocol guidelines of the University of Nebraska-Lincoln, Lincoln, NE, USA. The study was conducted in accordance with the National Institutes of Health guidelines for the use of experimental animals, and the protocols were specifically approved by the University of Nebraska-Lincoln Institutional Animal Care and Use Committee (permit number: A3459-01; protocol # 999).

2.2. Peptide synthesis and immunization procedures

PLP 139–151 (HSLGKWLGHPPDKF) and Theiler’s murine encephalomyelitis virus (TMEV) 70–86 (WTTSQAFSSHIRIPLP) were synthesized on 9-fluorenylmethyloxycarbonyl chemistry (Neopeptide, Cambridge, MA, USA). TMEV 70–86 peptide previously has been shown to bind MHC class II allele, IAs molecule in SJL mice (Massilamany et al., 2010, 2011a, 2011b; Lorenz et al., 1988; Reddy et al., 2003). Thus, we used TMEV 70–86 as a control peptide for PLP 139–151 in all assays. The peptides were HPLC-purified (90%), identity-confirmed by mass spectroscopy, and dissolved in sterile 1× PBS prior to use. Peptide emulsions involving PLP 139–151 were prepared in complete Freund’s adjuvant (CFA) containing Mycobacterium tuberculosis (M. tb, 1 mg/ml) H37RA extract (Difco Laboratories, Detroit, MI, USA), and administered subcutaneously into SJL mice (100 μg/mouse; n = 3) (Massilamany et al., 2010). At termination, animals were euthanized using a CO2 chamber prefilled with 2% CO2.

2.3. Generation of MHC class II dextramers

Dextramer reagents comprised of IAs/PLP 139–151 and IAs/TMEV 70–86 (control) were generated as described previously (Massilamany et al., 2011a). We have used IAs/PLP 70–86 dextramers as controls to ascertain TCR-binding specificity of IAs/PLP 139–151 dextramers, in all dextramer staining reactions (Massilamany et al., 2011a). Briefly, the α and β constructs of IAs allele along with the peptide of interest were expressed together using baculovirus expression systems in SF9 insect cells (Invitrogen, Carlsbad, CA). Soluble MHC class II monomers of IAs were then purified, concentrated, and biotinylated using biotin ligase (25 μg/10 nmol of substrate; Avidity, Denver, CO) (Massilamany et al., 2010, 2011a, 2011b). The biotinylated monomers were assembled to fluorophore conjugated dextran molecules (kindly provided by Immudex, Copenhagen, Denmark) at a molar ratio of 20:1 in 1× Tris HCl 0.05M, pH 7.2, by incubating in the dark for 30 min at room temperature (RT) (Massilamany et al., 2011a). The dextramer reagents were aliquoted and stored at 4 °C until use.

2.4. Generation of antigen-sensitized primary T cells

Ten days post-immunization with PLP 139–151, the draining lymph nodes (mandibular, axillary, inguinal, and popliteal) were collected and single cell suspensions were prepared. Lymph node cells (LNCs) were stimulated with PLP 139–151 (20 μg/ml) at a density of 5 × 106 cells/ml for two days in clone medium (RPMI medium supplemented with 10% fetal bovine serum [FBS], 1 mM sodium pyruvate, 4 mM L-glutamine, 1× each of non-essential amino acids and vitamin mixture, and 100 U/ml penicillin–streptomycin) (Lonza, Walkersville, MD) (Massilamany et al., 2010, 2011b, 2011c). After two days, the cultures were supplemented with clone medium containing interleukin (IL)-2 (hereafter called IL-2 medium) and maintained for an additional two days. Viable lymphoblasts were harvested on day 4 and maintained in IL-2 medium until fusion. In some experiments, LNCs obtained from immunized mice were expanded with concanavalin-A (Con-A, 1 μg/ml) at a density of 2 × 106 cells/ml for two days before fusion (Massilamany et al., 2014).

2.5. Fusion with BW5147 αβ−/− cells

Three approaches were adopted for the generation of antigen-specific T cell hybridoma clones (Figure 1).

2.5.1. Approach 1: derivation of T cell hybridomas using Con-A-stimulated T cells generated in immunized mice

LNCs stimulated with Con-A were harvested after 48 h, and cells were washed twice with DMEM (1× DMEM [HyClone laboratories, South Logan, UT]) containing 10% FBS, 1 mM sodium pyruvate, 7.5 mM L-glutamine, 0.66 M L-arginine [Fisher BioReagents, Fair Lawn, NJ], 0.27 M L-asparagine [MP Biomedical, LLC Solon, OH], 0.24 mM sodium bicarbonate [Sigma-Aldrich, St. Louis, MO], 10 mM HEPES [Roche Life Sciences, Indianapolis, IN], and 100 U/ml penicillin–streptomycin, 0.05 mM β-mercaptoethanol [PMD Biosciences, La Jolla, CA]). Cells were then mixed with BW5147 αβ−/− cells at a ratio of 1:4, washed once, and fused as described earlier (White et al., 2000; Kruisbeek, 2001; Canaday, 2013; Kohler et al., 1977). The tube containing the cell pellet was placed in a 37 °C water bath, and 0.4 ml of 50% polyethylene glycol (PEG) in 75 mM HEPES (Roche Life Sciences) was gently added in a circular motion over a 1-minute period. After stirring the pellet for an additional minute, a total of 10 ml of pre-warmed DMEM with 10% FBS (hereafter called hybridoma medium) was delivered, 1 ml during the first minute, followed by another ml during the second minute, and the rest (8 ml) during the next 2 min (1 ml/15 s) as the mixture was gently stirred continuously (White et al., 2000; Kruisbeek, 2001; Canaday, 2013). After washing with hybridoma medium, cells were plated in 96-well plates at a density of 3.6 × 104 cells/ml (5 × 105 cells/140 μl/well; Figure 1).

2.5.2. Approach 2: generation of T cell hybridomas using antigen-stimulated T cells generated in vitro

Viable lymphoblasts were harvested on day 4 poststimulation with PLP 139–151 and fused with BW5147 αβ−/− cells at a ratio of 1:3; the cells were plated as above in 96-well plates (Figure 1).

2.5.3. Approach 3: generation of T cell hybridomas using the MHC class II dextramer+ cells sorted by flow cytometry

Viable lymphoblasts were harvested on day 4 poststimulation with PLP 139–151 and rested in IL-2 medium for two days. Cells were then stained with the dextramers (IAs/PLP 139–151 and con-
trol dextramers) in dextramer-staining medium (IL-2 medium containing 2.5% FBS, pH 7.63) at RT for 2 h (Massilamany et al., 2011a). After washing, PLP 139–151 dextramer-stained cells were incubated with a cocktail of antibodies for the predominant TCR vβs expressed by PLP-reactive cells (Massilamany et al., 2011d) (vβ 2, 3, 4, 6, 14 and 17a; BD Pharmingen, San Diego, CA), and anti-CD4 (eBioscience, San Diego, CA). Cells were then washed and the live CD4+ dextramer+ vβ+ cells were sorted by flow cytometry (FACSAria, BD Biosciences, San Jose, CA). Cells were washed and rested in IL-2 medium for 5 days, at which time dextramers bound to the cells were no longer detectable by flow cytometry, leading us to fuse these cells with BW5147 αβ−/− cells (1:5 ratio). After being washed and acquired by a flow cytometer, vβ+ CD3+ CD4+ T cell hybridoma clones were analyzed in the live (7-AAD−) population. Finally, by using PLP 139–151 dextramers, and vβ antibodies, cells positive for both were identified. To obtain single clones, cells stained as above with the specific anti-TCR vβ were sorted with one cell per well into 96-well plates containing hybridoma medium. Plates were incubated until visible clones were observed, which occurred between days 10 to 14 postsorting. Positive clones were gradually expanded and reascertained for dextramer positivity. Clones were labeled appropriately and preserved in liquid nitrogen until further use.

2.7. Measurement of proliferative responses

To assess the functional responsiveness of T cell clones, we used tritiated [3H]-thymidine-incorporation assay. Briefly, hybridoma clones were cultured in clone medium in the presence of irradiated (3000 rad) syngeneic LNC/splenocytes pulsed with PLP 139–151 as antigen-presenting cells at a ratio of 1:5 (1 × 10^5:5 × 10^4) for 20 h. After pulsing with [3H]-thymidine for 16 h, proliferative responses were measured as counts per minute.
using MHC class II dextramers to generate antigen-specific T cell hybridomas

2.8. Analysis of chemokine receptor expression

The surface expression of chemokine receptors (CCRs) was analyzed using antibodies for CCR4, CCR5, or CCR6, anti-CD4, and 7-AAD. After washing, cells were acquired by flow cytometry, and percent-ages of chemokine receptor-expressing cells were determined in the live (7-AAD−) population using FlowJo software. The clones of anti-chemokine receptor antibodies used were: CCR-4 (2G12), CCR-5 (HMCCR5) and CCR-6 (29-2L17), all from BioLegend, San Diego, CA.

2.9. Cytokine measurement

The ability of T cell hybridomas to secrete different cytokines was assessed by intracellular staining (Massilamany et al., 2010, 2011c; Evavold et al., 1994; Nakajima et al., 2001; Wilde et al., 1992). Cells were stimulated with phorbol 12-myristate-13 acetate (PMA, 10 ng/ml) and ionomycin (150 ng/ml, Sigma-Aldrich) for 5 h in the presence of 1 mM monensin (Golgi stop, BD Pharmingen). After staining with anti-CD4 and 7-AAD, cells were fixed, permeabilized, and stained with anti-cytokine antibodies or with the respective isotype controls. After washing, the cells were acquired by flow cytometry, and the frequencies of cytokine-producing cells were determined in the live (7-AAD−) CD4 population using FlowJo software. The clones of anti-cytokine antibodies used were: IL-2 (JES6-5H4), interferon (IFN)-γ (XMG1.2), IL-4 (11B11), IL-10 (JES5-16E3), IL-17A (eBio17B7), and tumor necrosis factor (TNF)-α (MP6-XT22), all from eBioscience.

3. Results and discussion

We demonstrated the utility of using MHC class II dextramers to create CD4 T cell hybridomas for PLP 139–151 that induce experimental autoimmune encephalomyelitis in SJL (H-2s) mice. The use of MHC class II dextramers offered few advantages: 1). The dextramers could be used as screening tools to verify the antigen specificity of potential clones as early as 10 to 12 days after fusion. In conjunction with other T cell markers (CD3, CD4, CD8, and TCR/vβs) the use of dextramers allowed us to identify antigen-specific clones by flow cytometry in a single step. 2). After identifying positive clones, we could derive mono antigen-specific clones by sorting the cells with one cell per well using dextramers. 3). Unlike the traditional method that requires a large number of antigen-sensitized T cells (up to 5 × 10⁷ cells), successful fusions could be achieved with as few as ~7.6 × 10⁵ dextramers+ cells. Overall, the time required to obtain clones can be cut down significantly, and all steps from immunizations to cloning single cells can be finished in 7–8 weeks.

As we reported previously, dextramers were found to be helpful in detecting the rare antigen-specific, autoreactive CD4 T cells, which was not possible using tetramers, both ex vivo, and in situ within target organs such as the hearts and brains (Massilamany et al., 2011a, 2014a, 2014b). Unlike MHC class II tetramers that contain no more than four biotinylated MHC/peptide complexes because only a single streptavidin moiety is available, a large number of MHC/peptide complexes (up to 20) can be assembled to each dextran backbone in dextramers, because multiple streptavidin moieties (6 to 7) are available for binding the biotinylated MHC molecules (Massilamany et al., 2011a; Batard et al., 2006). As a result, large aggregates of MHC/peptide complexes can be generated through dextramers, leading to enhanced avidity for binding to T cells by engaging multiple TCRs. Thus, using dextramers could increase detection sensitivity by at least 5-fold, as compared with use of tetramers (Massilamany et al., 2011a). Although derivation of T cell hybridomas for PLP 139–151 has been reported previously (Donermeyer et al., 1995;

Figure 2. Screening of T cell hybridomas for antigen specificity. Pools of cells representing 16 wells in 48-well plates were prepared, and the cells were stained with IAAs/MHC class II dextramers (PLP 139–151 and control). Pools that were positive for PLP 139–151 dextramers were identified, then individual wells containing the dextramer+ cells were identified. Cells in these wells were tested for both TCR vβs and dextramers; the double-positive cells were sorted by flow cytometry with one cell per well; and their antigen-specificity was reconfirmed.

Table 1. Evaluation of TCR vβ-usage in PLP 139–151 dextramer+ CD4+ T cell hybridoma clones.

<table>
<thead>
<tr>
<th>Well ID</th>
<th>Dextramer staining</th>
<th>Panel of TCR vβ antibodies used</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>vβ2</td>
</tr>
<tr>
<td>A9</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>A17</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>A31</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>D19</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>D26</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>E48</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>H2</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>H15</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>I14</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>I29</td>
<td>+</td>
<td>−</td>
</tr>
</tbody>
</table>
Kuchroo et al., 1994), we took advantage of the availability of dextramer reagents for this antigen to demonstrate their utility for deriving antigen-specific T cell hybridomas quickly and efficiently, by exploring three different approaches (Figure 1).

### 3.1. Approach 1: derivation of T cell hybridomas using Con-A-stimulated T cells generated in immunized mice

Con-A is traditionally used as a mitogen to stimulate unprimed polyclonal T cell populations that permit assessment of the overall immunocompetence in physiological and clinical conditions (Stone et al., 2009; Kruisbeek et al., 2004; Krammer et al., 1982). Here, we used this reagent to expand antigen-sensitized T cells ex vivo with an expectation that they may get enriched upon activation, thus allowing their availability to be more in number for fusions. We used LNcs sensitized with PLP 139–151 from immunized mice, and, after expansion with Con-A for two days, cells were fused, expecting that viable clones could be directly screened by dextramers for their antigen specificity. The fused cells were plated in ten 96-well plates (10 × 96 = 960 wells), and, after 12 days, successful fusions as indicated by viability/growth of cells were noted in 30% of the wells (288/960 × 100). We then made 18 pools, each representing cells from 16 wells for staining with PLP 139–151 dextramers (Figure 2). Contrary to our expectations, we did not detect the pools positive for staining with PLP 139–151 dextramers. Such an outcome was not surprising, however, given the low frequencies of antigen-sensitized T cells present in the ex vivo LNcs populations (Jenkins and Moon, 2012). We had previously determined the frequency of PLP 139–151-specific cells to be 0.12% of total CD4 T cells in immunized SJL mice (Massilamany et al., 2011a). We had predicted that Con-A-stimulation might sufficiently facilitate the expansion of antigen-specific T cells to allow us to obtain a few clones, but this was not the case. Alternatively, this approach may still prove to be successful if CD4 T cells enriched from immunized animals are used as a starting population for fusions, but we did not investigate this possibility.

### 3.2. Approach 2: generation of T cell hybridomas using antigen-stimulated T cells generated in vitro

Here, we fused the effector T cells generated from PLP 139–151 immunized mice with BWS147 αβ−/− cells (Rock, 1985; White et al., 2000; Kruisbeek, 2001). LNcs were obtained from immunized SJL mice, and after stimulating the cells with PLP 139–151 and resting them in IL-2 medium, viable lymphoblasts were used for fusions (Figure 1). We used dextramer reagents (IAs/PLP 139–151, and control) for screening and cloning antigen-specific hybridomas as a novel strategy in a step-wise fashion (Figure 2).

#### 3.2.1. Step 1

To generate PLP 139–151-specific hybridomas, eight 96-well plates were plated with the fused cells (8 × 96 = 768 wells). Successful fusions, indicated by viability/growth of cells, were noted in 62.5% of the wells (480/768 × 100). We then made 30 pools, each consisting of cells from 16 wells, and tested them for staining with PLP 139–151 dextramers. Such an outcome was not surprising, however, given the low frequencies of antigen-sensitized T cells present in the ex vivo LNcs populations (Jenkins and Moon, 2012). We had predicted that Con-A-stimulation might sufficiently facilitate the expansion of antigen-specific T cells to allow us to obtain a few clones, but this was not the case. Alternatively, this approach may still prove to be successful if CD4 T cells enriched from immunized animals are used as a starting population for fusions, but we did not investigate this possibility.

#### 3.2.2. Step 2

In this step, cells in the dextramer+ wells were screened for TCR vβ-usage. Since, dextramer+ cells in each well could contain more than one clone, potentially with different vβ-usage, we decided to first screen each of the 10 wells of PLP 139–151-dextramer+ clones with a panel of vβ antibodies. The selected vβ panels were based on the published literature and our own data (Massilamany et al., 2011a). We had previously determined the frequency of PLP 139–151-specific cells to be 0.12% of total CD4 T cells in immunized SJL mice (Massilamany et al., 2011a). We had predicted that Con-A-stimulation might sufficiently facilitate the expansion of antigen-specific T cells to allow us to obtain a few clones, but this was not the case. Alternatively, this approach may still prove to be successful if CD4 T cells enriched from immunized animals are used as a starting population for fusions, but we did not investigate this possibility.

### Table 2. Derivation of PLP 139–151-specific hybridoma clones using PLP 139–151 dextramer+ cells sorted by flow cytometry as the starting population for fusions.

<table>
<thead>
<tr>
<th>Well ID</th>
<th>Dextramer staining</th>
<th>Panel of TCR vβ antibodies used</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>vβ2</td>
</tr>
<tr>
<td>A3</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A13</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A18</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A22</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A36</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A38</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>A47</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>B2</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B11</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B12</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B13</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B16</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B27</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

(Figure 1). We used dextramer reagents (IAs/PLP 139–151, and control) for screening and cloning antigen-specific hybridomas as a novel strategy in a step-wise fashion (Figure 2).

#### 3.2.2. Step 2

In this step, cells in the dextramer+ wells were screened for TCR vβ-usage. Since, dextramer+ cells in each well could contain more than one clone, potentially with different vβ-usage, we decided to first screen each of the 10 wells of PLP 139–151-dextramer+ clones with a panel of vβ antibodies. The selected vβ panels were based on the published literature and our own data (Massilamany et al., 2011a). We had previously determined the frequency of PLP 139–151-specific cells to be 0.12% of total CD4 T cells in immunized SJL mice (Massilamany et al., 2011a). We had predicted that Con-A-stimulation might sufficiently facilitate the expansion of antigen-specific T cells to allow us to obtain a few clones, but this was not the case. Alternatively, this approach may still prove to be successful if CD4 T cells enriched from immunized animals are used as a starting population for fusions, but we did not investigate this possibility.

### Table 2. Derivation of PLP 139–151-specific hybridoma clones using PLP 139–151 dextramer+ cells sorted by flow cytometry as the starting population for fusions.

<table>
<thead>
<tr>
<th>Well ID</th>
<th>Dextramer staining</th>
<th>Panel of TCR vβ antibodies used</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>vβ2</td>
</tr>
<tr>
<td>A3</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A13</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A18</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A22</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A36</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>A38</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>A47</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>B2</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B11</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B12</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B13</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B16</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>B27</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

(Figure 1). We used dextramer reagents (IAs/PLP 139–151, and control) for screening and cloning antigen-specific hybridomas as a novel strategy in a step-wise fashion (Figure 2).

#### 3.2.2. Step 2

In this step, cells in the dextramer+ wells were screened for TCR vβ-usage. Since, dextramer+ cells in each well could contain more than one clone, potentially with different vβ-usage, we decided to first screen each of the 10 wells of PLP 139–151-dextramer+ clones with a panel of vβ antibodies. The selected vβ panels were based on the published literature and our own data (Massilamany et al., 2011a).

### Figure 3. Generation of antigen-specific, single cell clones by flow cytometry. To obtain single cell clones, cells were stained with IAs/dextramers (PLP 139–151 and control), CD4 and vβ17a or vβ2 antibodies and 7-AAD. Through flow cytometric analysis, PLP 139–151 dextramer+ vβ+ cells were sorted with one cell per well, and after expansion, their antigen-specificity was reconfirmed by dextramer staining as described above.
using MHC class II dextramers to generate antigen-specific T cell hybridomas

2011c, 2011d; Kuchroo et al., 1992; Whitham et al., 1993). Through these analyses we identified wells showing positive staining for up to six vβs for PLP 139–151 (vβ2, vβ3, vβ4, vβ6, vβ14 and vβ17a; Table 1). Of note, for analysis of vβ-expressing dextramer+ cells, it was critical to stain with dextramers first, followed by staining with vβ antibodies (Massilamany et al., 2011d). Staining with the above reagents in reverse order allows detection of only vβ+ cells, and as such, the proportion of dextramer+ cells can be absent or significantly reduced, indicating that vβ-antibodies can sterically hinder dextramers from binding to TCRs.

3.2.3. Step 3
After identifying the wells positive for both dextramers and specific vβs, we sought to provide a proof-of-principle that single cell clones can be obtained by flow cytometric sorting of dextramer+ cells. To this end, we selected two wells (A9 and D26; Table 1) and sorted the cells positive for PLP 139–151 dextramers and anti-vβ17a or anti-vβ2 respectively with a single cell per well into one 96-well plate for each. We obtained a total of 31 viable clones, and rescreening of these by dextramer staining led us to identify at least ten clones to be highly positive for PLP 139–151 dextramers (Figure 3).

3.3. Approach 3: generation of T cell hybridomas using the MHC class II dextramer+ cells sorted by flow cytometry
In this approach, we asked whether dextramer+ T cells could be used as a starting population for fusing the cells, expecting the dextramer+ clones to be antigen specific, thus avoiding the multi-step procedure described in approach 2. We addressed this question by sorting the antigen-specific CD4 T cells from LNC cultures de-

![Figure 4](image-url)

**Figure 4.** Phenotypic and functional characterization of selected T cell hybridomas. (a) Surface markers. Three T cell hybridoma clones, specific for PLP 139–151 were selected, and expression of CD3, CD4, CD8, and TCRs was characterized by flow cytometry. (b) Antigen specificity. Antigen specificity of the selected clones was tested by dextramer staining, and proliferative responses as evaluated by flow cytometry and [3H]-thymidine incorporation assay, respectively. The experimental details are as described in the Materials and methods section. PLP 139–151: specific antigen; TMEV 70–86: control antigen. Representative data from three to four individual experiments are shown.
rived from SJL mice immunized with PLP 139–151. For sorting PLP 139–151-specific cells, we used PLP 139–151 or control dextramers, anti-CD4, and a mixture of anti-vβs (vβ2, 3, 4, 6, 14 and 17a). We sorted a total of $7.6 \times 10^5$ dextramer+ vβ+ cells by flow cytometry, and after resting the cells in IL-2-medium for 5 days, the cells were fused with BW5147 αβ−/− cells, followed by plating in one 96-well plate. We noted successful fusions as indicated by viable clones in 78 wells (78 / 96 × 100 = 81.3%). A total of 16 pools, each represented by cells from 3 to 5 wells, were then stained with PLP 139–151 dextramers, leading us to identify 10 positive pools. Cells from each of 50 wells (10 pools × 5) were then screened for staining with dextramers leading us to identify at least 14 wells that were positive for dextramers (14/50 × 100 = 28%), which were then examined for vβ-expression using selected TCR vβ antibodies, as shown in Table 2. Expectedly, cells in each well showed positive staining for more than one vβ, suggesting the presence of multiple clones in a given well (Table 2). Thus, we have provided a proof of principle that antigen-specific T cell hybridoma clones can be obtained using dextramer+ cells as a starting population for fusions.

Overall, the relative successful cell-fusion frequencies obtained from all the three approaches were in the order of approach 3 (81.3%) followed by approach 2 (62.5%), and approach 1 (30%). Similarly, screening of these fusions also led us to identify 28% of wells to contain antigen (PLP 139–151)-specific hybridoma clones with approach 3 as opposed to 7.8% with approach 2, and none with approach 1.

After generating the T cell hybridomas for PLP 139–151, we sought to characterize their phenotypes. We selected three clones (A9/17, A9/23, and A9/24; Figure 3); all of them showed the expression of CD3, CD4 and TCR (Figure 4a). We then evaluated antigen
specificity based on dextramer staining and proliferative responses. Expectedly, all PLP 139–151-specific clones could be stained with the corresponding dextramers but not with control dextramers (Figure 4b: top panel). Next, we asked whether PLP 139–151-specific clones can functionally respond to antigens. Using [3H]-thymidine incorporation assay, it was clear that all PLP 139–151-specific clones responded to PLP 139–151 stimulation, but the net outcome was reduced proliferative response likely due to cell death as reported by others (Dönmeyer et al., 1995; Shi et al., 1989, 1990; Waldner et al., 2000), which occurred only with PLP 139–151 but not with the control antigen (Figure 4b: bottom panel). Thus, we identified functionally responsive clones for PLP 139–151. Finally, we asked whether the functionalities of antigen-specific T cell hybridomas can be distinguished based on chemokine receptor expression and cytokine synthesis (Figure 5). By testing for chemokine receptors CCR4, CCR5, and CCR6 as the putative markers for Th2, Th1, and Th17 phenotypes (Islam and Luster, 2012; Wu et al., 2001), respectively, only CCR4 was found to be present in all PLP 139–151-specific clones (Figure 5a). However, testing for their cytokine producing ability by intracellular staining revealed that one PLP 139–151-specific clone (A9/23) was positive for IL-2 and IL-4, whereas two other clones (A9/17 and A9/24) showed only marginal production of IL-2 (Figure 5b). None of the clones showed any detectable staining for other cytokines (proinflammatory cytokines IFN-γ, IL-17A, and TNF-α and the anti-inflammatory cytokine IL-10; data not shown) indicating that the cytokine-producing ability of T cell hybridomas is largely restricted to T cell growth factors. Similar observations have been made with T cell hybridoma clones specific to various other antigens (Rock, 1985; Hagihara et al., 1988).

4. Conclusions

In summary, we have demonstrated the utility of MHC class II dextramers for cloning antigen-specific CD4 T cell hybridomas using PLP 139–151 as an autoantigen. We have previously reported that dextramers are expected to bind T cells bearing high-affinity TCRs and therefore propose that the hybridoma clones obtained by using dextramers might carry such TCRs. However, in spite of enhanced detection sensitivity, dextramers cannot detect the complete repertoire of antigen-specific T cells as we previously demonstrated (Massilamany et al., 2011a). Thus, we cannot conclude that dextramer– clones are not antigen-specific, and the clones possibly expressing the low-affinity TCRs might be undetected by dextramers. Nonetheless, if MHC class II dextramer-bound T cells are to be interpreted as T cells bearing high affinity TCRs, then the availability of dextramer-detectable hybridoma clones can serve as useful tools for various applications, such as screening peptide libraries to identify antigenic epitopes, epitope mimics, altered peptide ligands, and chemical analogues of activating ligands; studies related to antigen processing and presentation pathways; production of TCR-specific monoclonal antibodies; in vivo tracking of antigen-specific T cells; and other molecular and functional studies that involve interactions with TCRs (Rock, 1985; Canaday et al., 2003; Depta et al., 2004; Green et al., 1994; Zumla et al., 1992). One caveat to keep in mind about dextramer-assisted generation of T cell hybridomas is that the availability of MHC dextramers for antigens of interest is absolutely critical, but their generation per se may be a time-consuming process. Should the dextramer reagents be made available, then derivation of T cell hybridomas can be accomplished rapidly in a limited time-frame of 7–8 weeks.

Acknowledgments — This work was supported by the National Institutes of Health (HL114669). CM is a recipient of a postdoctoral research fellowship grant awarded by the Myocarditis Foundation, NJ. The authors wish to confirm that there are no known conflicts of interest associated with this publication.

References


